Drugs / unlicensed CBU
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01656603 | Feb 2012 → Dec 2030 expected | — | New York Blood Center | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | unlicensed CBU | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01656603 ↗ |
| Known as | HPC-CORD BLOOD | “The primary aim of this study is to examine the safety of administration of the unlicensed investigational NCBP hematopoietic progenitor cell-cord blood (HPC-CORD BLOOD)...” NCT01656603 ↗ |
| Modality | Cell therapy | “hematopoietic progenitor cell-cord blood (HPC-CORD BLOOD) products” NCT01656603 ↗ |
| Route | Other | “infusion of unlicensed cord blood units” NCT01656603 ↗ |